Affiliation:
1. Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Shenzhen 518055, China
2. Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
Abstract
Aims: The automation of quantitative evaluation for breast immunohistochemistry (IHC) plays a crucial role in reducing the workload of pathologists and enhancing the objectivity of diagnoses. However, current methods face challenges in achieving fully automated immunohistochemistry quantification due to the complexity of segmenting the tumor area into distinct ductal carcinoma in situ (DCIS) and invasive carcinoma (IC) regions. Moreover, the quantitative analysis of immunohistochemistry requires a specific focus on invasive carcinoma regions. Methods and Results: In this study, we propose an innovative approach to automatically identify invasive carcinoma regions in breast cancer immunohistochemistry whole-slide images (WSIs). Our method leverages a neural network that combines multi-scale morphological features with boundary features, enabling precise segmentation of invasive carcinoma regions without the need for additional H&E and P63 staining slides. In addition, we introduced an advanced semi-supervised learning algorithm, allowing efficient training of the model using unlabeled data. To evaluate the effectiveness of our approach, we constructed a dataset consisting of 618 IHC-stained WSIs from 170 cases, including four types of staining (ER, PR, HER2, and Ki-67). Notably, the model demonstrated an impressive intersection over union (IoU) score exceeding 80% on the test set. Furthermore, to ascertain the practical utility of our model in IHC quantitative evaluation, we constructed a fully automated Ki-67 scoring system based on the model’s predictions. Comparative experiments convincingly demonstrated that our system exhibited high consistency with the scores given by experienced pathologists. Conclusions: Our developed model excels in accurately distinguishing between DCIS and invasive carcinoma regions in breast cancer immunohistochemistry WSIs. This method paves the way for a clinically available, fully automated immunohistochemistry quantitative scoring system.
Funder
National Natural Science Foundation of China
Shenzhen Science and Technology Innovation Commission
Jilin Fuyuan Guan Food Group Co., Ltd.
Reference40 articles.
1. Global Cancer Statistics 2022: The trends projection analysis;Chhikara;Chem. Biol. Lett.,2023
2. WHO (2019). WHO Classification of Tumors–Breast Tumors, International Agency for Research on Cancer. [5th ed.].
3. Comparison of breast cancer risk factors among molecular subtypes: A case-only study;Zhang;Cancer Med.,2019
4. Significance of immunohistochemistry in breast cancer;Zaha;World J. Clin. Oncol.,2014
5. Dabbs, D.J. (2021). Diagnostic Immunohistochemistry E-Book: Theranostic and Genomic Applications, Elsevier.